Showing 181-185 of 259 resources:
OM1 Artificial Intelligence (AI) Shared Decision Aid Demonstrates Significant Improvement In Decision Quality And Surgical Outcomes For Knee Osteoarthritis

BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]

Putting Real-World Data & AI to Work for Rare Diseases

Thu, Feb 25, 2021 11:00 AM – 12:00 PM EST Register Accessibility to real-world data (RWD) and advances in artificial intelligence (AI) driven models and technologies make a powerful combination in advancing research and development efforts. So how do we use these new tools to tackle the challenges in developing and launching new treatments for[…]

OM1 Heart Failure Registry Reaches More Than 140,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry. Heart Failure (HF) is considered a growing healthcare epidemic and is associated with significant mortality, morbidity and resource utilization. In the United States, HF is estimated to[…]

OM1 Giant Cell Arteritis Registry Reaches More Than 5,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, Dec. 8, 2020 /PRNewswire/ — OM1, a leading real-world, data, outcomes and technology company with a focus on chronic diseases, today announced the expansion of its Giant Cell Arteritis (GCA) registry. GCA, also known as temporal arteritis, is a chronic inflammatory artery disease that causes head pain, joint pain, vision problems, and fever. GCA affects approximately 230,000 Americans,[…]